N-(3-甲酰基苯基)苯磺酰胺 | 151721-35-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(3-甲酰基苯基)苯磺酰胺
• 中文别名: N-(3-甲酰苯基)苯磺酰胺；N-(3-甲烷酰苯基)苯磺酰胺
• 英文名称: N-(3-formylphenyl)benzenesulfonamide
• CAS: 151721-35-6
• 化学式: C₁₃H₁₁NO₃S
• mdl: MFCD06017220
• 分子量: 261.301
• InChiKey: XYNPRCCUVAUTHD-UHFFFAOYSA-N

物化性质

• 熔点：
  104 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(3-甲酰基苯基)苯磺酰胺 在 potassium tert-butylate 作用下， 生成 (2E,4E)-5-[3-(Benzenesulfonyl-methyl-amino)-phenyl]-penta-2,4-dienoic acid ethyl ester
  参考文献：
  名称：

  （2E）-5- [3-[（[苯磺酰基）氨基]苯基]-戊-2-en-4-氨基异羟肟酸及其衍生物作为ras转化的新型有效抑制剂。

  摘要：

  DOI：

  10.1021/jm960174k

文献信息

• BENZENE DERIVATIVE
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：US20210332009A1

  公开（公告）日：2021-10-28

  A compound represented by general formula (I) (in the formula, all symbols are as described in the description) or a salt thereof has a potent nerve-protecting and/or -repairing activity, and therefore can be used as a therapeutic agent for neuropathy (e.g., chronic inflammatory demyelinating polyneuropathy, Guillain-Barre syndrome, periarteritis nodosa, allergic vasculitis, diabetic peripheral neuropathy, entrapment neuropathy, peripheral neuropathy associated with the administration of a chemotherapeutic drug, or peripheral neuropathy associated with Charcot-Marie-Tooth disease).

  通式（I）表示的化合物（在公式中，所有符号如描述中所述）或其盐具有强大的神经保护和/或修复活性，因此可用作神经病变的治疗剂（例如，慢性炎症性脱髓鞘性多发性神经病、吉兰-巴雷综合征、周围动脉炎、过敏性血管炎、糖尿病周围神经病变、神经卡压病变、与化疗药物治疗相关的周围神经病变，或与沙科-玛丽-图斯病相关的周围神经病变）。
• [EN] PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060112A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及具有式（I）的新化合物，其能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物可用于治疗多种疾病。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• Indazole derivatives
  申请人：Ohta Yoshihisa

  公开号：US20070117856A1

  公开（公告）日：2007-05-24

  The present invention provides a compound represented by Formula (I): [wherein R 1 represents CONR 1a R 1b (wherein R 1a and R 1b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or R 1a and R 1b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group) or the like, R 2 represents a hydrogen atom, CONR 2a R 2b (wherein R 2a and R 2b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or R 2a and R 2b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group), NR 2c R 2d (wherein R 2c and R 2d may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroaroyl, substituted or unsubstituted ararkyl, substituted or unsubstituted lower alkylsulfonyl or substituted or unsubstituted lower arylsulfonyl) or the like].

  本发明提供了一个由公式（I）表示的化合物：[其中R1表示CONR1aR1b（其中R1a和R1b可以相同或不同，每个表示氢原子，取代或未取代的较低烷基，取代或未取代的芳基，取代或未取代的芳基烷基或取代或未取代的杂环基，或R1a和R1b与相邻的氮原子结合形成取代或未取代的杂环基）或类似物，R2表示氢原子，CONR2aR2b（其中R2a和R2b可以相同或不同，每个表示氢原子，取代或未取代的较低烷基，取代或未取代的芳基，取代或未取代的芳基烷基或取代或未取代的杂环基，或R2a和R2b与相邻的氮原子结合形成取代或未取代的杂环基），NR2cR2d（其中R2c和R2d可以相同或不同，每个表示氢原子，取代或未取代的较低烷基，取代或未取代的较低烷酰基，取代或未取代的芳酰基，取代或未取代的杂环芳酰基，取代或未取代的芳基烷基磺酰基或取代或未取代的较低芳基磺酰基）或类似物]。
• INDAZOLE DERIVATIVES
  申请人：Ohta Yoshihisa

  公开号：US20090082348A1

  公开（公告）日：2009-03-26

  The present invention provides a compound represented by Formula (I): [wherein R 1 represents CONR 1a R 1b (wherein R 1a and R 1b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or R 1a and R 1b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group) or the like, R 2 represents a hydrogen atom, CONR 2a R 2b (wherein R 2a and R 2b may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted aryl, substituted or unsubstituted ararkyl or a substituted or unsubstituted heterocyclic group, or R 2a and R 2b are combined together with the adjacent nitrogen atom thereto to form a substituted or unsubstituted heterocyclic group), NR 2c R 2d (wherein R 2c and R 2d may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aroyl, substituted or unsubstituted heteroaroyl, substituted or unsubstituted ararkyl, substituted or unsubstituted lower alkylsulfonyl or substituted or unsubstituted lower arylsulfonyl) or the like].

  本发明提供了一个由公式（I）表示的化合物：[其中R1表示CONR1aR1b（其中R1a和R1b可以相同或不同，每个代表氢原子，取代或未取代的较低烷基，取代或未取代的芳基，取代或未取代的芳基烷基或取代或未取代的杂环基，或R1a和R1b与相邻的氮原子结合形成取代或未取代的杂环基）或类似物，R2表示氢原子，CONR2aR2b（其中R2a和R2b可以相同或不同，每个代表氢原子，取代或未取代的较低烷基，取代或未取代的芳基，取代或未取代的芳基烷基或取代或未取代的杂环基，或R2a和R2b与相邻的氮原子结合形成取代或未取代的杂环基），NR2cR2d（其中R2c和R2d可以相同或不同，每个代表氢原子，取代或未取代的较低烷基，取代或未取代的较低烷酰基，取代或未取代的芳酰基，取代或未取代的杂环芳酰基，取代或未取代的芳基烷基磺酰基或取代或未取代的芳基磺酰基）或类似物]。
• PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS
  申请人：ORIGENIS GMBH

  公开号：US20150266882A1

  公开（公告）日：2015-09-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及化合物(I)的新型化合物，能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物在治疗多种疾病方面有应用。这些疾病包括自身免疫疾病、炎症性疾病、骨病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼病、传染病和激素相关疾病。